Tempus AI | 8-K: Tempus Reports Fourth Quarter and Full Year 2025 Results

Tempus AI reported strong Q4 2025 results with revenue reaching $367.2M, up 83% YoY, driven by 121.6% growth in Diagnostics revenue to $266.9M and 25.1% growth in Data and Applications revenue to $100.4M. Oncology and Hereditary testing volumes grew 29% and 23% respectively, while MRD testing volume increased 56% QoQ to ~4,700 tests.The company achieved positive Adjusted EBITDA of $12.9M in Q4, improving from -$7.8M in Q4 2024. Gross profit increased 94.7% YoY to $237.7M, though net loss was $54.2M including $48.7M in stock compensation expenses. The company ended 2025 with $759.7M in cash and marketable securities.Looking ahead, Tempus provided 2026 revenue guidance of $1.59B, representing ~25% annual growth, and expects Adjusted EBITDA of approximately $65M. The company maintains strong business momentum with over $1.1B in Total Remaining Contract Value and 126% Net Revenue Retention.

Tempus AI reported strong Q4 2025 results with revenue reaching $367.2M, up 83% YoY, driven by 121.6% growth in Diagnostics revenue to $266.9M and 25.1% growth in Data and Applications revenue to $100.4M. Oncology and Hereditary testing volumes grew 29% and 23% respectively, while MRD testing volume increased 56% QoQ to ~4,700 tests.The company achieved positive Adjusted EBITDA of $12.9M in Q4, improving from -$7.8M in Q4 2024. Gross profit increased 94.7% YoY to $237.7M, though net loss was $54.2M including $48.7M in stock compensation expenses. The company ended 2025 with $759.7M in cash and marketable securities.Looking ahead, Tempus provided 2026 revenue guidance of $1.59B, representing ~25% annual growth, and expects Adjusted EBITDA of approximately $65M. The company maintains strong business momentum with over $1.1B in Total Remaining Contract Value and 126% Net Revenue Retention.